NO20041331L - Anvendelse av Calmodulin kinase II inhibitorer for a behandle myokardial dysfunksjon i strukturell hjertesykdom - Google Patents

Anvendelse av Calmodulin kinase II inhibitorer for a behandle myokardial dysfunksjon i strukturell hjertesykdom

Info

Publication number
NO20041331L
NO20041331L NO20041331A NO20041331A NO20041331L NO 20041331 L NO20041331 L NO 20041331L NO 20041331 A NO20041331 A NO 20041331A NO 20041331 A NO20041331 A NO 20041331A NO 20041331 L NO20041331 L NO 20041331L
Authority
NO
Norway
Prior art keywords
heart disease
structural heart
inhibitors
myocardial dysfunction
treat myocardial
Prior art date
Application number
NO20041331A
Other languages
English (en)
Other versions
NO20041331D0 (no
Inventor
Mark Anderson
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of NO20041331D0 publication Critical patent/NO20041331D0/no
Publication of NO20041331L publication Critical patent/NO20041331L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en metode for behandling av strukturell hjertesykdom hos et individ, som omfatter administrering av en effektiv mengde av en inhibitor for CaMKII til individet, hvorved administrering av inhibitoren behandler den strukturelle hjertesykdom hos individet.Det tilveiebringes også transgene dyremodeller for behandling av strukturell hjertesykdom.Videre tilveiebringes en metode for screening for en forbindelse som kan behandle strukturell hjertesykdom.
NO20041331A 2001-10-01 2004-03-31 Anvendelse av Calmodulin kinase II inhibitorer for a behandle myokardial dysfunksjon i strukturell hjertesykdom NO20041331L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32657601P 2001-10-01 2001-10-01
US32801001P 2001-10-08 2001-10-08
PCT/US2002/031496 WO2003029428A2 (en) 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease

Publications (2)

Publication Number Publication Date
NO20041331D0 NO20041331D0 (no) 2004-03-31
NO20041331L true NO20041331L (no) 2004-05-28

Family

ID=26985461

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041331A NO20041331L (no) 2001-10-01 2004-03-31 Anvendelse av Calmodulin kinase II inhibitorer for a behandle myokardial dysfunksjon i strukturell hjertesykdom

Country Status (14)

Country Link
US (2) US7320959B2 (no)
EP (1) EP1439849A4 (no)
JP (1) JP2005504829A (no)
KR (1) KR20040045041A (no)
CN (1) CN1599622A (no)
AU (1) AU2002341938B2 (no)
BR (1) BR0213043A (no)
CA (1) CA2462443A1 (no)
IL (1) IL161231A0 (no)
MX (1) MXPA04003040A (no)
NO (1) NO20041331L (no)
NZ (1) NZ532327A (no)
PL (1) PL369104A1 (no)
WO (1) WO2003029428A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006049215A1 (ja) * 2004-11-02 2008-05-29 大日本住友製薬株式会社 自己免疫疾患を治療するための併用薬
ES2431578T3 (es) * 2008-04-09 2013-11-27 B.R.A.H.M.S Gmbh Proendotelina-1 para la predicción del consumo de oxígeno máximo disminuido
US8841423B2 (en) * 2008-04-28 2014-09-23 University Of Iowa Research Foundation Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
US20090275514A1 (en) * 2008-05-01 2009-11-05 Anderson Mark E Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation
US9506032B2 (en) * 2009-05-22 2016-11-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered biological pacemakers
US8440656B2 (en) * 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
CN102711785A (zh) * 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
AU2014225889B2 (en) 2013-03-06 2018-12-06 The Johns Hopkins University CaMKII inhibitors and uses thereof
DE102014201651A1 (de) * 2014-01-30 2015-07-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen
AU2015311730A1 (en) 2014-09-05 2017-04-20 Allosteros Therapeutics, Inc Camkii inhibitors and uses thereof
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
CN112972447B (zh) * 2021-03-02 2022-09-23 扬州大学附属医院 CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (no) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
EP0966274B1 (en) * 1997-01-31 2002-06-12 The Board Of Trustees Of The Leland Stanford Junior University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
JP2963986B2 (ja) * 1997-11-19 1999-10-18 工業技術院長 カルモジュリン依存性リン酸化酵素ｉｉの特異的阻害剤

Also Published As

Publication number Publication date
NZ532327A (en) 2005-10-28
US20040266675A1 (en) 2004-12-30
AU2002341938B2 (en) 2007-08-30
KR20040045041A (ko) 2004-05-31
BR0213043A (pt) 2004-10-05
JP2005504829A (ja) 2005-02-17
US7320959B2 (en) 2008-01-22
EP1439849A4 (en) 2005-09-28
PL369104A1 (en) 2005-04-18
NO20041331D0 (no) 2004-03-31
CN1599622A (zh) 2005-03-23
IL161231A0 (en) 2004-09-27
MXPA04003040A (es) 2004-07-15
WO2003029428A8 (en) 2004-04-22
US20090011989A1 (en) 2009-01-08
EP1439849A2 (en) 2004-07-28
WO2003029428A3 (en) 2003-10-30
WO2003029428A2 (en) 2003-04-10
US7632815B2 (en) 2009-12-15
CA2462443A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
NO20041331L (no) Anvendelse av Calmodulin kinase II inhibitorer for a behandle myokardial dysfunksjon i strukturell hjertesykdom
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
BR0008188A (pt) Inibidores de fator de diferenciação de crescimento e usos para os mesmos
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
BR0317183A (pt) Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
ATE424208T1 (de) Proteinkinaseinhibitoren
EA201100604A1 (ru) Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
DE60318177D1 (de) Rho-kinase inhibitoren
WO2004089297A3 (en) Compounds and methods for treatment of thrombosis
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
NO20063572L (no) Kinazolinditosylatsalt forbindelser
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
EA200500191A1 (ru) Кристаллический 2,5-дион-3-(1-метил-1h-индол-3-ил)-4-[1-(пиридин-2-илметил)пиперидин-4-ил]-1h-индол-3-ил]-1h-пирролмоногидрохлорид
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE443044T1 (de) Tace inhibitoren

Legal Events

Date Code Title Description
ERR Erratum

Free format text: I PATENTTIDENDE NR. 22/07 BLE PATENTSOKNAD NR. 20034598 OG 20041331 FEILAKTIG KUNNGJORT HENLAGT. SOKNADENDE ER FORTSATT UNDER BEHANDLING

Free format text: I PATENTTIDENDE NR. 22/07 BLE PATENTSOKNAD NR. 20034598 OG 20041331 FEILAKTIG KUNNGJORT HENLAGT. SOKNADENDE ER FORTSATT UNDER BEHANDLING.

FC2A Withdrawal, rejection or dismissal of laid open patent application